Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 48

1.

Reply.

Cardet JC, Jiang X, Lu Q, Gerard N, McIntire K, Boushey HA, Castro M, Chinchilli VM, Codispoti CD, Dyer AM, Holguin F, Kraft M, Lazarus S, Lemanske RF, Lugogo N, Mauger D, Moore WC, Moy J, Ortega VE, Peters SP, Smith LJ, Solway J, Sorkness CA, Sumino K, Wechsler ME, Wenzel S, Israel E; AsthmaNet Investigators.

J Allergy Clin Immunol. 2019 Jul 9. pii: S0091-6749(19)30751-1. doi: 10.1016/j.jaci.2019.05.029. [Epub ahead of print] No abstract available.

PMID:
31300279
2.

Mometasone or Tiotropium in Mild Asthma with a Low Sputum Eosinophil Level.

Lazarus SC, Krishnan JA, King TS, Lang JE, Blake KV, Covar R, Lugogo N, Wenzel S, Chinchilli VM, Mauger DT, Dyer AM, Boushey HA, Fahy JV, Woodruff PG, Bacharier LB, Cabana MD, Cardet JC, Castro M, Chmiel J, Denlinger L, DiMango E, Fitzpatrick AM, Gentile D, Hastie A, Holguin F, Israel E, Jackson D, Kraft M, LaForce C, Lemanske RF Jr, Martinez FD, Moore W, Morgan WJ, Moy JN, Myers R, Peters SP, Phipatanakul W, Pongracic JA, Que L, Ross K, Smith L, Szefler SJ, Wechsler ME, Sorkness CA; National Heart, Lung, and Blood Institute AsthmaNet.

N Engl J Med. 2019 May 23;380(21):2009-2019. doi: 10.1056/NEJMoa1814917. Epub 2019 May 19.

PMID:
31112384
3.

Loss of bronchoprotection with ICS plus LABA treatment, β-receptor dynamics, and the effect of alendronate.

Cardet JC, Jiang X, Lu Q, Gerard N, McIntire K, Boushey HA, Castro M, Chinchilli VM, Codispoti CD, Dyer AM, Holguin F, Kraft M, Lazarus S, Lemanske RF, Lugogo N, Mauger D, Moore WC, Moy J, Ortega VE, Peters SP, Smith LJ, Solway J, Sorkness CA, Sumino K, Wechsler ME, Wenzel S, Israel E; AsthmaNet Investigators.

J Allergy Clin Immunol. 2019 Mar 11. pii: S0091-6749(19)30347-1. doi: 10.1016/j.jaci.2019.01.049. [Epub ahead of print]

PMID:
30872116
4.

Rapid onset of effect of benralizumab on morning peak expiratory flow in severe, uncontrolled asthma.

Chupp G, Lugogo NL, Kline JN, Ferguson GT, Hirsch I, Goldman M, Zangrilli JG, Trudo F.

Ann Allergy Asthma Immunol. 2019 May;122(5):478-485. doi: 10.1016/j.anai.2019.02.016. Epub 2019 Feb 23.

5.

Use of a Cross-Sectional Survey in the Adult Population to Characterize Persons at High-Risk for Chronic Obstructive Pulmonary Disease.

Pleasants RA, Heidari K, Ohar J, Donohue JF, Lugogo N, Richard CL, Kanotra S, Mannino DM, Kraft M, Liao W, Strange C.

Healthcare (Basel). 2019 Jan 18;7(1). pii: E12. doi: 10.3390/healthcare7010012.

6.

Adapting clinical trial design to maintain meaningful outcomes during a multicenter asthma trial in the precision medicine era.

Sorkness CA, King TS, Dyer AM, Chinchilli VM, Mauger DT, Krishnan JA, Blake K, Castro M, Covar R, Israel E, Kraft M, Lang JE, Lugogo N, Peters SP, Wechsler ME, Wenzel SE, Lazarus SC; National Heart Lung and Blood Institute's “AsthmaNet”.

Contemp Clin Trials. 2019 Feb;77:98-103. doi: 10.1016/j.cct.2018.12.012. Epub 2018 Dec 27.

PMID:
30593883
7.

Obesity and adult asthma: diagnostic and management challenges.

Grace J, Mohan A, Lugogo NL.

Curr Opin Pulm Med. 2019 Jan;25(1):44-50. doi: 10.1097/MCP.0000000000000531.

PMID:
30394901
8.

Bacterial biogeography of adult airways in atopic asthma.

Durack J, Huang YJ, Nariya S, Christian LS, Ansel KM, Beigelman A, Castro M, Dyer AM, Israel E, Kraft M, Martin RJ, Mauger DT, Rosenberg SR, King TS, White SR, Denlinger LC, Holguin F, Lazarus SC, Lugogo N, Peters SP, Smith LJ, Wechsler ME, Lynch SV, Boushey HA; National Heart, Lung and Blood Institute’s “AsthmaNet”.

Microbiome. 2018 Jun 9;6(1):104. doi: 10.1186/s40168-018-0487-3.

9.

Medication Regimens for Managing Stable Asthma.

Meghdadpour S, Lugogo NL.

Respir Care. 2018 Jun;63(6):759-772. doi: 10.4187/respcare.05957. Review.

10.

Reply.

Lugogo NL, Green C, Kraft M.

J Allergy Clin Immunol. 2018 Aug;142(2):713-714. doi: 10.1016/j.jaci.2018.02.030. Epub 2018 Apr 11. No abstract available.

PMID:
29655585
11.

Effect of the S-nitrosoglutathione reductase inhibitor N6022 on bronchial hyperreactivity in asthma.

Que LG, Yang Z, Lugogo NL, Katial RK, Shoemaker SA, Troha JM, Rodman DM, Tighe RM, Kraft M.

Immun Inflamm Dis. 2018 Jun;6(2):322-331. doi: 10.1002/iid3.220. Epub 2018 Apr 11.

12.

Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease.

Pavord ID, Chanez P, Criner GJ, Kerstjens HAM, Korn S, Lugogo N, Martinot JB, Sagara H, Albers FC, Bradford ES, Harris SS, Mayer B, Rubin DB, Yancey SW, Sciurba FC.

N Engl J Med. 2017 Oct 26;377(17):1613-1629. doi: 10.1056/NEJMoa1708208. Epub 2017 Sep 11.

13.

Assessing the impact of a remote digital coaching engagement program on patient-reported outcomes in asthma.

Rasulnia M, Burton BS, Ginter RP, Wang TY, Pleasants RA, Green CL, Lugogo N.

J Asthma. 2018 Jul;55(7):795-800. doi: 10.1080/02770903.2017.1362430. Epub 2017 Oct 11.

PMID:
28800273
14.

Obesity's effect on asthma extends to diagnostic criteria.

Lugogo N, Green CL, Agada N, Zhang S, Meghdadpour S, Zhou R, Yang S, Anstrom KJ, Israel E, Martin R, Lemanske RF Jr, Boushey H, Lazarus SC, Wasserman SI, Castro M, Calhoun W, Peters SP, DiMango E, Chinchilli V, Kunselman S, King TS, Icitovic N, Kraft M.

J Allergy Clin Immunol. 2018 Mar;141(3):1096-1104. doi: 10.1016/j.jaci.2017.04.047. Epub 2017 Jun 15.

15.

Obese asthmatic patients have decreased surfactant protein A levels: Mechanisms and implications.

Lugogo N, Francisco D, Addison KJ, Manne A, Pederson W, Ingram JL, Green CL, Suratt BT, Lee JJ, Sunday ME, Kraft M, Ledford JG.

J Allergy Clin Immunol. 2018 Mar;141(3):918-926.e3. doi: 10.1016/j.jaci.2017.05.028. Epub 2017 Jun 15.

16.

Income is an independent risk factor for worse asthma outcomes.

Cardet JC, Louisias M, King TS, Castro M, Codispoti CD, Dunn R, Engle L, Giles BL, Holguin F, Lima JJ, Long D, Lugogo N, Nyenhuis S, Ortega VE, Ramratnam S, Wechsler ME, Israel E, Phipatanakul W; Vitamin D Add-On Therapy Enhances Corticosteroid Disparities Working Group members on behalf of the AsthmaNet investigators.

J Allergy Clin Immunol. 2018 Feb;141(2):754-760.e3. doi: 10.1016/j.jaci.2017.04.036. Epub 2017 May 20.

17.

Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma.

Nair P, Wenzel S, Rabe KF, Bourdin A, Lugogo NL, Kuna P, Barker P, Sproule S, Ponnarambil S, Goldman M; ZONDA Trial Investigators.

N Engl J Med. 2017 Jun 22;376(25):2448-2458. doi: 10.1056/NEJMoa1703501. Epub 2017 May 22.

18.

Features of the bronchial bacterial microbiome associated with atopy, asthma, and responsiveness to inhaled corticosteroid treatment.

Durack J, Lynch SV, Nariya S, Bhakta NR, Beigelman A, Castro M, Dyer AM, Israel E, Kraft M, Martin RJ, Mauger DT, Rosenberg SR, Sharp-King T, White SR, Woodruff PG, Avila PC, Denlinger LC, Holguin F, Lazarus SC, Lugogo N, Moore WC, Peters SP, Que L, Smith LJ, Sorkness CA, Wechsler ME, Wenzel SE, Boushey HA, Huang YJ; National Heart, Lung and Blood Institute's “AsthmaNet”.

J Allergy Clin Immunol. 2017 Jul;140(1):63-75. doi: 10.1016/j.jaci.2016.08.055. Epub 2016 Nov 10.

19.

Related or not? Development of spontaneous Creutzfeldt-Jakob disease in a patient with chronic, well-controlled HIV: A case report and review of the literature.

Babi MA, Kraft BD, Sengupta S, Peterson H, Orgel R, Wegermann Z, Lugogo NL, Luedke MW.

SAGE Open Med Case Rep. 2016 Oct 13;4:2050313X16672153. eCollection 2016.

20.

Long-term Efficacy and Safety of Mepolizumab in Patients With Severe Eosinophilic Asthma: A Multi-center, Open-label, Phase IIIb Study.

Lugogo N, Domingo C, Chanez P, Leigh R, Gilson MJ, Price RG, Yancey SW, Ortega HG.

Clin Ther. 2016 Sep;38(9):2058-2070.e1. doi: 10.1016/j.clinthera.2016.07.010. Epub 2016 Aug 21.

Supplemental Content

Loading ...
Support Center